Maravai Lifesciences Holdings, INC Form 4 insider transactions

Luke Joseph Marker, a Director and 10% owner of Maravai LifeSciences Holdings, Inc., acquired 89,139 shares of Class A Common Stock as restricted stock units, holding them indirectly for a GTCR-affiliated entity.

Maravai LifeSciences Holdings, Inc. Director Gregory T. Lucier was awarded 89,139 restricted stock units, valued at $2.16 per unit, under the company's 2020 Omnibus Incentive Plan.

Maravai LifeSciences Holdings, Inc. Director Murali Prahalad was awarded 89,139 restricted stock units on June 16, 2025, increasing his beneficial ownership to 154,607 shares.

Maravai LifeSciences Holdings, Inc. Director Sean Laurence Cunningham was awarded 89,139 restricted stock units valued at $2.16 per share, vesting over one year or by the 2026 annual meeting.

Maravai LifeSciences Holdings, Inc. Director R. Andrew Eckert was granted 231,481 restricted stock units, with half vesting immediately and the remainder vesting in May 2026.

Maravai LifeSciences Holdings, Inc. Director Constantine S. Mihas reported the acquisition of 89,139 restricted stock units as part of an incentive plan.

Maravai LifeSciences Holdings, Inc. Director Jessica Hopfield was granted 89,139 restricted stock units (RSUs) valued at $2.16 per share, as part of the company's 2020 Omnibus Incentive Plan.

Maravai LifeSciences Holdings, Inc. Director John A. DeFord was granted 89,139 restricted stock units (RSUs) of Class A Common Stock, valued at $2.16 per unit, as part of the company's 2020 Omnibus Incentive Plan.

Maravai LifeSciences Holdings, Inc. CEO Bernd Brust was granted a substantial equity incentive package totaling 5.25 million shares, comprising restricted stock units, stock options, and performance stock units, aligning his long-term compensation with shareholder value.

Maravai LifeSciences Holdings, Inc.'s Chief Financial Officer, Kevin Herde, acquired 876 shares of Class A Common Stock at $1.67 per share through the company's Employee Stock Purchase Plan.

Christine Dolan, Executive Vice President at Maravai LifeSciences, acquired 2,381 shares of Class A Common Stock at $1.67 per share through the company's Employee Stock Purchase Plan.

Kevin Herde, CFO of Maravai LifeSciences Holdings, Inc., reports the acquisition of 394,478 shares of Class A Common Stock through restricted stock units.

General Counsel Kurt Oreshack reports acquiring Class A Common Stock and holding restricted stock units in Maravai LifeSciences Holdings, Inc.

Rebecca Buzzeo, Chief Commercial Officer of Maravai LifeSciences Holdings, reports acquiring 295,858 shares of Class A Common Stock through restricted stock units.

Peter Michael Leddy, Chief Administrative Officer of Maravai LifeSciences Holdings, Inc., reports acquiring 394,478 shares of Class A Common Stock through restricted stock units.

CEO William E. Martin III reports the acquisition of restricted stock units (RSUs) in Maravai LifeSciences Holdings, Inc.

Christine Dolan, an executive at Maravai LifeSciences, reports the acquisition of restricted stock units (RSUs) under the company's 2020 Omnibus Incentive Plan.

Kevin Herde, CFO of Maravai LifeSciences Holdings, Inc., reports the disposal of shares to cover tax obligations related to vesting restricted stock units.

Peter Leddy, Chief Administrative Officer of Maravai LifeSciences, reports disposition of shares to cover tax obligations related to vesting restricted stock units.

Kurt Oreshack, General Counsel of Maravai LifeSciences Holdings, reports the disposal of shares to cover tax obligations related to vesting restricted stock units.

Christine Dolan, an executive at Maravai LifeSciences, reported the disposal of shares to cover tax obligations related to vesting restricted stock units.

Rebecca Buzzeo, Chief Commercial Officer of Maravai LifeSciences, reports disposition of shares to cover tax obligations related to vesting restricted stock units.

Kurt Oreshack, General Counsel of Maravai LifeSciences Holdings, reports the disposal of 2,028 shares to cover tax obligations related to vesting restricted stock units.

Christine Dolan, an executive at Maravai LifeSciences, reported disposing of 1,621 shares to cover tax obligations related to vesting restricted stock units.

Kevin Herde, CFO of Maravai LifeSciences Holdings, Inc., reports the disposal of shares to cover tax obligations related to vesting restricted stock units.

Kurt Oreshack, General Counsel of Maravai LifeSciences, sold 25,000 shares of Class A Common Stock at $5.03 per share on January 31, 2025, under a pre-arranged 10b5-1 trading plan.

Maravai LifeSciences CEO William E. Martin III sold 160,981 shares of Class A Common Stock to cover tax obligations related to vesting restricted stock units.

Maravai LifeSciences CFO Kevin Herde sold 46,344 shares of Class A Common Stock to cover tax obligations related to vesting restricted stock units.

Andrew Burch, a former executive at Maravai LifeSciences, sold 54,412 shares of Class A Common Stock to cover tax obligations related to vesting restricted stock units.

Rebecca Buzzeo, Chief Commercial Officer of Maravai LifeSciences, sold 45,456 shares of Class A Common Stock to cover tax obligations related to vesting restricted stock units.